[ad_1] Biotechnology firm Biocon Ltd on Friday (March 7) said its subsidiary Biocon Biologics Ltd has announced positive results from its phase 3 clinical trial for Yesintek, a biosimilar to ustekinumab (marketed as Stelara). The randomised, double-blind, parallel-group, multi-centre study evaluated Yesintek in adult patients with moderate to severe chronic plaque psoriasis (PsO). The findings, […]
Biocon Biologics launches Stelara biosimilar YESINTEK in US for autoimmune diseases – CNBC TV18
[ad_1] Biotechnology firm Biocon Ltd on Monday (February 24) said its unit Biocon Biologics announced the US market availability of YESINTEK (ustekinumab-kfce), a biosimilar to Stelara (ustekinumab). This makes YESINTEK one of the first biosimilar alternatives to enter the US market for the blockbuster immunology drug. Company Value Change %Change YESINTEK is approved for the […]